Liaoning Chengda Biotechnology Co.,Ltd. (SHA:688739)

Market Cap	10.89B
Revenue (ttm)	1.47B
Net Income (ttm)	177.94M
Shares Out	411.25M
EPS (ttm)	0.43
PE Ratio	61.48
Forward PE	27.59
Dividend	0.80 (3.02%)
Ex-Dividend Date	Jun 10, 2025

Volume	2,535,936
Average Volume	1,988,899
Open	26.47
Previous Close	26.55
Day's Range	26.38 - 26.64
52-Week Range	23.80 - 29.90
Beta	0.67
RSI	49.61
Earnings Date	Apr 21, 2026

About SHA:688739

Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company’s rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,807
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688739

Financial Performance

In 2024, SHA:688739's revenue was 1.68 billion, a decrease of -4.22% compared to the previous year's 1.75 billion. Earnings were 342.82 million, a decrease of -26.42%.